Updates

Texas Children's Cancer and Hematology Center

Clinical Trials and Novel Therapies

As a recognized leader in clinical and laboratory research, we offer clinical trials and novel therapies for a wide range of children’s cancer and blood disorders.

Children treated through a clinical trial have better outcomes. Because of this over 80% of our patients are involved in a clinical trial or study. With over 250 active therapeutic clinical trials, our >350 researchers and 47 laboratories are pioneering the translation of discoveries to the clinic. As part of larger teams, our experts collaborate with the pharmaceutical industry and participate in major pediatric cancer and blood disorder cooperative clinical trial groups, like the Children’s Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC). Through these efforts, we are proud to offer the most advanced care possible. See below for our current and featured trials. 

GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Read More

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)

Study aims to determine the optimal safe dosage of GD2-CAR NKT cells (GINAKIT cells), assess their impact on neuroblastoma tumors, duration of detection in patient blood, and their influence on neuroblastoma outcomes in children.

Read More

Vinblastine/Prednisone versus Single Therapy with Cytarabine for Langerhans Cell Histiocytosis (LCH)

Study for patients newly diagnosed with Langerhan's cell histiocytosis to compare vinblastine/prednisone  versus cytarabine (LCH-REASON).

Read More

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Phase 1 immunotherapy trial using next generation CD30.CAR T cells  for refractory lymphoma (Hodgkin or non-Hodgkin, including ALCL) (RELY 30).

Read More

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

Phase 1 trial using next generation CD5.CAR T cells for recurrent T-cell leukemia/lymphoma (MAGENTA).

Read More

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Gene transfer study available only at our Center for patients with refractory or recurrent B cell Acute Lymphoblastic Leukemia (B-ALL) with expression of CD19, CD20 and/or CD22.

Read More

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination with Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Phase 1 immunotherapy trial for children with relapsed or refractory sarcoma using a combination of HER2-CAR T cells with checkpoint blockade (HEROS 3.0).

Read More

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI)

Frontline study of cobimetinib in patients with recurrent or refractory histiocytic diseases (NACHO COBI).

Read More

New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers

Phase 1 immunotherapy trial using 15.GPC3-CAR T cells for children with solid tumors, including liver, kidney and other rare cancers.

Read More

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (CRIMSON)

Phase 1 cell therapy for children with high-risk T-cell malignancies using CD7-specific CAR expressed on autologous T cells (CRIMSON).

Read More

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Study to evaluate Eltrombopag for newly diagnosed immune thrombocytopenia (ITP) in children.

Read More

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (ONITT)

Phase 1 study of irinotecan liposomal with talazoparib or temozolomide in children with recurrent solid tumors or Ewing sarcoma (ONITT).

Read More

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

A Phase 2 study for alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (EPIK-P2).

Read More

Evaluation of the Safety and Efficacy of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis

Evaluation of ELA026 monoclonal antibody for safety and efficacy as a treatment for patients with secondary hemophagocytic lymphohistiocytosis.

Read More

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

Phase 2 trial for MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency or CDC42 mutations (MASter-1).

Read More

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children with Ependymoma (PBTC-059)

A multi-center HER2-CAR T-cell immunotherapy trial for children with relapsed or refractory ependymoma (PBTC-059).

Read More

For a complete list of clinical trials offered at Texas Children's Hospital, visit clinicaltrials.gov

Ranked #6 in Cancer

Proud to be ranked one of the best children’s cancer centers in the country by U.S. News & World Report for seven consecutive years.